Sunteți pe pagina 1din 35

CADASIL

Mechanisms of disease
Anne JOUTEL

Mechanisms of CADASIL: key issues

?
SMC/pericytes

a-Notch3ECD

1. The earliest cerebrovascular changes?


2. Notch3 receptor malfunction? 3. Mechanisms of Notch3ECD/GOM deposits formation? 4. Novel function gained by mutant Notch3?

Modeling CADASIL in the mouse to define the earliest cerebrovascular changes


Background Strain(s) Mouse (K-in) R142C Mouse (K-in) R170C TgSM22ahumN3R90C TgSM22ahumN3C428S humN3C455RStop/ lox; TgSM22aCre humN3R1031CStop /lox; TgSM22aCre TgPACratN3R169C
? 129/swiss C57BL/6

Notch3 expression level


endogenous endogenous Overexpression SMC promoter (~1 fold) SMC promoter Overexpression (~1.5 fold) SMC promoter Overexpression ? SMC promoter overexpression ? Notch3 promoter overexpression (~4 fold)

Notch3ECD / GOM
+/+ +/+

Migraine/ CSD
nd nd +

White matter lesions


-

Lacunar infarcts
(?) 7% -

Motor / cognitive deficits


? 12% -/nd

C57BL/6

+/+

nd

-/nd

129/BL6

nd/+

nd

-/nd

129/BL6

nd/+

nd

-/nd

FVB

+/+

nd

-/nd

Joutel; bioessays, 2011

TgPAC-Notch3R169C mice recapitulate the presymptomatic stage of the disease


White matter changes GOM deposits Notch3ECD deposits 0 1 6 12 20 months

a-N3ECD

a-MBP Joutel et al, J. Clin Invest. 2010 Cognat et al, in preparation

Ultrastructural correlate of initial white matter lesions: intramyelinic oedema


E

F
Myelin- associated vacuoles (%)

Cognat et al, in preparation

Vacuoles (%)

Secondary axonal degeneration

a-MBP a-NF

Cognat et al, in preparation

Preserved integrity of Blood-Brain-Barrier

Joutel et al, J. Clin Invest. 2010

No overt arterial stenosis

Joutel et al, J. Clin Invest. 2010

Impaired adaptative responses of CBF prior to the occurrence of brain lesions

A- CBF autoregulation

B- Functional hyperemia

Joutel et al, J. Clin Invest. 2010

Arterial & arteriolar myogenic responses are attenuated


A B- pial arteries

C- intraparenchymal arterioles

Joutel et al, J. Clin Invest. 2010 Dabertrand, Joutel & Nelson, in preparation

The earliest cerebrovascular changes in TgPAC-Notch3R169C mice

Myelin vacuolation > axonal degeneration GOM deposits

Notch3ECD deposits

12 Cerebral hypoperfusion

20 months

Capillary regression Cerebrovascular dysfunction

Key issues

?
SMC/pericytes

a-Notch3ECD

The earliest cerebrovascular changes?


Notch3 receptor malfunction? Mechanisms of Notch3ECD/GOM deposits formation? Novel function gained by mutant Notch3?

Notch3 plays a key role in the structure and function of small arteries

Ligands (Jagged1)

Arterial morphogenesis (brain)


Notch3 S1 S2 S3 NICD

Arterial SMC differentiation and maturation Arterial tone Transcriptional activator: Notch3, Grip2, Nrip2, HeyL, Kv1.5...

RBPJ GTGGGAA

Domenga et al, Genes & Dev 2004 Prowler et al, PNAS 2007 Belin de Chantemle et al, ATVB 2008 Fouillade et al, Cardiovasc Res. 2012 Fouillade et al, ATVB 2013

A few CADASIL mutations in the ligand binding domain abolish Notch3 activity
15

% of Mutations

10

Ligand binding

34 EGFR

RBPJ-LacZ

Monet et al, HMG 2007 Monet et al, Brain 2009

Knock-in mice with the archetypal Arg170/169Cys mutation retain normal Notch3 signaling in the brain arteries A

Cognat et al, submitted

Elimination of wildtype Notch3 in TgN3R169C mice does not exacerbate white matter lesions

> Reduced Notch3 activity is unlikely the driving force in CADASIL


Cognat et al, submitted

Key issues

?
SMC/pericytes

a-Notch3ECD

The earliest cerebrovascular changes?


Notch3 receptor malfunction? Mechanisms of Notch3ECD/GOM deposits formation? Novel function gained by mutant Notch3?

Notch3ECD deposits occur independently of ligand activation of the receptor

Ligands (Jagged1)

Notch3C428S
S1

TghN3WT,N3+/+
S2

TghN3C428S,N3+/+

TghN3C428S,N3-/-

S3

RBPJ

Notch3ECD is a component of GOM deposits


a-Notch3ECD

SMC

Joutel et al, JCI 2000 Ishiko et al, Acta Neuropathol 2006 Monet-Leprtre et al, Brain 2013

Mutant Notch3ECD accumulates in disulfide cross-linked, detergent-insoluble aggregates


A B

Brain arteries RIPA 25,000g S1 P1 SDS2% 25,000g S2 P2 Laemmli+me 25,000g S3 P3

Notch3ECD

RIPA

SDS 2%

laemmli+ me

S1

S2

S3

Nano LC MS/MS
Monet-Leprtre et al, Brain 2013

TIMP3 accumulates in the brain vessels of mouse models and patients with CADASIL

nonTg

TgN3R169C

control

patient

a-Notch3ecd

a-TIMP3 a-SMA

TIMP3 deposits with Notch3ECD in GOM

A a-TIMP3

control

patient

patient

patient

patient

a-TIMP3

a-N3ecd

merge

a-TIMP3

Vitronectin abnormally deposits in Notch3EC aggregates in CADASIL brain vessels


TgNotch3WT

a-Vtn

a-N3ecd

merge

TgNotch3R169C a-Vtn control a-Vtn a-N3ecd patient

merge patient

Monet-Leprtre et al, Brain 2013

Excess Notch3ECD promotes TIMP3-Notch3ECD interaction and TIMP3 accumulation


A B C

Monet-Leprtre et al, Brain 2013

TIMP-3 interacts with Vitronectin and promotes Notch3-Vitronectin complex formation


A B

Monet-Leprtre et al, Brain 2013

Proposed model for Notch3ECD/GOM deposits formation

(1)

(2)

(3)

(4)

WT

Mutant Notch3

TIMP3

Vitronectin

Others

Key issues

?
SMC/pericytes

a-Notch3ECD

The early (potentially causative) cerebrovascular changes? Notch3 receptor malfunction? Mechanisms of Notch3ECD/GOM deposits formation? Novel function gained by mutant Notch3?

General properties of the four Tissue inhibitor metalloproteinases (TIMPs)


Location TIMP1 TIMP2 Secreted in the ECM Secreted in the ECM Bound to the ECM MMPs inhibited All MMPs ADAM10 All MMPs Other functions Strong inhibitor of MMP9 Activates MMP2 Genetic disorder

TIMP3

All MMPs ADAM10 ADAM17 (TACE) All

- Apoptosis - Inhibits angiogenesis (VEGFR2) Inhibits angiogenesis

Sorbsby fundus dystrophy

TIMP4

Secreted in the ECM

From Rosenberg GA, Lancet Neurol 2009

Increasing TIMP3 expression impairs cerebrovascular responses


A
Hum BAC 419C14 (193kB) TIMP3

B
a-TIMP3

30-kDa 20-kDa

a-SMA

40-kDa

TIMP3 protein level (fold change)

non-Tg TgBAC-TIMP3(2)

8 7 6 5 4 3 2 1 0 non-Tg TgBAC-TIMP3

C. Capone & A. Joutel

Reducing TIMP3 rescues cerebrovascular dysfunction in TgNotch3R169C mice


A

B
Myogenic responses (% passive diameter)

pressure

C. Capone, C. Baron & A. Joutel

Superfusion of TIMP3, but neither of TIMP1 nor of TIMP2, impairs neurovascular function
A B Notch3R169C TIMP3

?
MMPs C
40

TIMPs

rTIMP2 topical (1mg/mL)

D
40

rTIMP1 topical (1mg/mL)

CBF (% increase)

30 20 10 0

CBF (% increase)
Whisker Ringer
n=5

30 20 10 0

ACh

Adenosine Timp2(1mg/mL)

Whisker Ringer
n=5

ACh

Adenosine Timp1(1mg/mL)

C. Capone & A. Joutel

ADAM-17 (TACE) superfusion ameliorates neurovascular dysfunction in TgTIMP3 and TgNotch3R169C mice
A Notch3R169C TIMP3 B

?
ADAM17 (TACE) C D

C. Capone & A. Joutel

The Notch3ECD cascade hypothesis


Cysteine mutation

Notch3ECD deposits

Matrisome of the neurovascular unit (TIMP3..)

Cerebrovascular dysfunction

Reduction Capillary bed

Structural alterations Brain arteries

Energetics/ionic homeostasis failure

CADASIL team- 2013

ALUMNI B. Bardot (post-doc), S. Cleophax (tech Staff), C. Dussaule (MSc student), P. Fardoux (PhD student), C. Fouillade (PhD student), P. Lacombe (Scientist), B. Lemaire (tech Staff), M. Monet-Leprtre (PhD student, post-doc), M. Fouillot-Pancha (tech Staff), M. Riani (MSc student)

Collaborators
I Haddad & J. Vinh (ESPCI, Paris, France) M. Cohen-Tannoudji & C. Babinet+ (Pasteur Institute, Paris, France) L Mesnard & E. Rondeau (Inserm, Paris, France) D. Henrion (Inserm, Angers, France) M Dewerchin (VIB, Leuven, Belgium) C. Gosele & N. Hbner (MDC Berlin, Germany) C. Haffner & M. Dichgans (Ludwig-Maximilians-University, Munich, Germany) H. Stoehr & B. Weber (Regensburg University, Germany) S. Christensen, J. Stavenhagen & J. Pedersen (Lundbeck, Valbi, Denmark) T. Gridley (Jackson Lab, Bar Harbor, USA) K. Takamiya & R. Huganir (The Johns Hopkins University School of Medicine, Baltimore, USA)F. Cenk Ayata & M. Moskowitz (Harvard Medical School, Charlestown, USA) Dabertrand & MT Nelson (University of Vermont, Burlington, USA) Brain banks : S. Turbant (GIE-NeuroCeb, Paris), JJ. Hauw (CHU Pitie-Salpetrire, Paris), F. Chapon (CHU Caen), C. Godfraind (Clinique St Luc, Bruxelles, Belgium), H. Kalimo (University of Turku, Finland), T. Arzberger (Brain Net, Munich, Germany) Facilities: C. Martin (Transgenic Mouse facility, TAAM, Villejuif), C. Thibault (MicroArray facility, IGBMC, Illkirch), J.P. Rio (Electron microscopy facility, IFM, Paris) Funding : National Institute Health (NINDS), European Community (Marie Curie ITN), Agence Nationale de la Recherche, Fondation Leducq, H Lundbeck A/S, Inserm, Universit Paris 7, Gis Maladies Rares, Fondation pour la Recherche Mdicale, Fdration pour la Recherche pour le Cerveau

S-ar putea să vă placă și